trending Market Intelligence /marketintelligence/en/news-insights/trending/zpziz-4omrdpz6hq_s2ftg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Abbott to close acquisition of St. Jude Medical on Jan. 4, 2017

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency

Groups Urge Business Roundtable CEOs To Act On New Corporate Purpose Declaration

State of South Korean OTT Video: Subscription

Global Streaming Media Device Sales Forecast To Flatten In 5 Year Outlook


Abbott to close acquisition of St. Jude Medical on Jan. 4, 2017

Abbott Laboratories plans to close its $25 billion acquisition of St. Jude Medical Inc. on Jan. 4, 2017.

The company has received all necessary regulatory approvals for the deal.

The acquisition is expected to be accretive to Abbott's adjusted EPS in the first full year and will increase after that, with about 21 cents of accretion in 2017 and an estimated 29 cents in 2018. It is also expected to result in annual pre-tax synergies of $500 million by 2020, including both sales and operational benefits.

The companies' combined cardiovascular and neuromodulation portfolio has annual sales of about $8.7 billion.